利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

94 条记录 (耗时 0.049 秒)

    STEERING DEVICE
    5.
    发明申请
    STEERING DEVICE 有权
    转向装置

    公开(公告)号：US20120198956A1

    公开(公告)日：2012-08-09

    申请号：US13363299

    申请日：2012-01-31

    申请人： Naoyuki TAKEZAWA ,  Yoshiyuki Sato

    发明人： Naoyuki TAKEZAWA ,  Yoshiyuki Sato

    IPC分类号： B62D1/187

    CPC分类号： B62D1/184 ,  B62D1/189

    摘要： A steering device includes an outer column including fastening pieces formed to face each other at both sides, in the width direction, of a slot portion formed at either of a lower side or an upper side of an embracing body portion along an axial direction thereof, a fixed bracket clamping the outer column, a fastener that fastens the outer column and the fixed bracket, an inner column, and a pushing member having an expanding shaft portion. The two fastening pieces of the embracing body portion are connected by the fastener so that the two fastening pieces can be expanded and contracted, and the expanding shaft portion is elastically biased in an axial center direction of the outer column so as to abut on end zones of the slot portion and expand the two fastening pieces.

    摘要翻译： 转向装置包括外柱，该外柱包括形成为沿宽度方向彼此面对的紧固件，所述紧固件形成在沿其轴向方向的包围主体部分的下侧或上侧的槽部中， 夹紧外柱的固定支架，紧固外柱和固定支架的紧固件，内柱和具有扩张轴部分的推动构件。 包围主体部分的两个紧固件通过紧固件连接，使得两个紧固件可以膨胀和收缩，并且扩展轴部分沿外柱的轴向中心方向弹性偏置，以便抵靠端部区域 并扩大两个紧固件。

    Novel aminopyrimidine derivatives as PLK1 inhibitors
    6.
    发明申请
    Novel aminopyrimidine derivatives as PLK1 inhibitors 有权
    新型氨基嘧啶衍生物作为PLK1抑制剂

    公开(公告)号：US20080305081A1

    公开(公告)日：2008-12-11

    申请号：US12002546

    申请日：2007-12-18

    申请人： Takashi Hashihayata ,  Mikako Kawamura ,  Morihiro Mitsuya ,  Yoshiyuki Sato

    发明人： Takashi Hashihayata ,  Mikako Kawamura ,  Morihiro Mitsuya ,  Yoshiyuki Sato

    IPC分类号： A61K38/21 ,  C07D471/04 ,  A61K39/395 ,  A61K33/24 ,  A61K38/50 ,  A61P35/00 ,  A61K31/506

    CPC分类号： C07D471/04

    摘要： The present invention relates to a compound represented by Formula [I]: or a pharmaceutically acceptable salt or ester thereof, wherein R1 and R2, which may be the same or different, are each a hydrogen atom, a lower alkyl group, a cycloalkyl group, or the like; R3 and R4, which may be the same or different, are each a hydrogen atom, a lower alkyl group, NRaRb, a phenyl group, a lower alkyl group substituted with a phenyl group, a 4- to 7-membered aliphatic heterocyclic group, a lower alkyl group substituted with a 4- to 7-membered aliphatic heterocyclic group, a 5- or 6-membered aromatic heterocyclic group, a lower alkyl group substituted with a 5- or 6-membered aromatic heterocyclic group, or the like; and R5 is a hydrogen atom, a cyano group, a halogen atom, or a lower alkyl group.

    摘要翻译： 本发明涉及由式[I]表示的化合物或其药学上可接受的盐或酯，其中R 1和R 2可以相同或不同，分别为氢原子，低级烷基，环烷基 ，等等; R 3和R 4可以相同或不同，分别为氢原子，低级烷基，NR a R b，苯基，被苯基取代的低级烷基，4-至7-元脂族杂环基， 被4-至7-元脂族杂环基取代的低级烷基，5或6元芳族杂环基，被5或6元芳族杂环基取代的低级烷基等; R5为氢原子，氰基，卤素原子或低级烷基。

    Isoindole derivatives
    9.
    发明授权
    Isoindole derivatives 失效
    异吲哚衍生物

    公开(公告)号：US06777410B2

    公开(公告)日：2004-08-17

    申请号：US10408220

    申请日：2003-04-08

    申请人： Toshio Nagase ,  Tomoharu Iino ,  Yoshiyuki Sato ,  Teruyuki Nishimura ,  Jun-ichi Eiki

    发明人： Toshio Nagase ,  Tomoharu Iino ,  Yoshiyuki Sato ,  Teruyuki Nishimura ,  Jun-ichi Eiki

    IPC分类号： A61K31423

    CPC分类号： C07D498/04

    摘要： This invention relates to compounds represented by the general formula [I] wherein, R represents an azido group, etc., R1 and R2 are the same or different and represent hydrogen atoms, etc., R3 and R4 are the same or different and represent hydrogen atoms, etc., X1 represents an oxygen atom, etc., X2 represents an oxygen atom, etc., Y represents an oxygen atom, etc., and Z represents a condensed aryl group, etc., or a pharmaceutically acceptable salt thereof, preparation processes thereof, and an agent for treating diabetes, a prophylactic agent for chronic complications of diabetes or a drug against obesity, containing, as an effective ingredient, the compound or the pharmaceutically acceptable salt thereof.

    摘要翻译： 本发明涉及由通式[I]表示的化合物，其中R表示叠氮基等，R 1和R 2相同或不同，表示氢原子等，R 3， 和R 4相同或不同，表示氢原子等，X 1表示氧原子等，X 2表示氧原子等，Y表示氧原子等，Z表示缩合 芳基等，或其药学上可接受的盐，其制备方法和用于治疗糖尿病的药物，用于糖尿病慢性并发症的预防剂或抗肥胖药物，其含有作为有效成分的化合物或药学上可接受的盐 其可接受的盐。

    Method for manufacturing heat-curable resin molded product
    10.
    发明授权
    Method for manufacturing heat-curable resin molded product 有权
    热固性树脂成型体的制造方法

    公开(公告)号：US06468460B2

    公开(公告)日：2002-10-22

    申请号：US09330919

    申请日：1999-06-11

    申请人： Shigeru Kinpara ,  Yoshiyuki Sato ,  Hisayoshi Osumi ,  Senji Suzuki

    发明人： Shigeru Kinpara ,  Yoshiyuki Sato ,  Hisayoshi Osumi ,  Senji Suzuki

    IPC分类号： B29C4514

    CPC分类号： B29C39/405 ,  B29C33/70 ,  B29C37/005 ,  B29C45/0025 ,  B29C45/4421

    摘要： When molding of a heat-curable resin such as unsaturated polyester resin and the like is conducted by means of the casting method, concavities in the molded product generated as a result of the curing shrinkage of this resin are prevented. A central core member comprising ABS resin or the like is disposed in advance within mold, a heat-curable resin liquid is injected thereinto, and heated, and at this time, an amount of expansion in the volume of central core member is caused which corresponds to the amount of volume shrinkage resulting from curing of the heat-curable resin, and the expansion of the central core member is synchronized with the curing shrinkage of the heat-curable resin.

    摘要翻译： 当通过流延法进行诸如不饱和聚酯树脂等热固性树脂的模塑时，可以防止由于该树脂的固化收缩而产生的模制品中的凹凸。 包括ABS树脂等的中心芯部件预先设置在模具内，将热固性树脂液体注入其中并进行加热，此时，引起中心芯体的体积膨胀量 与由该固化性树脂固化而产生的体积收缩量相对应，并且中心芯体的膨胀与热固性树脂的固化收缩同步。